Acepodia, Inc.

6976

KYG0073G1091

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
27.75 ^TWD	-1.42%		-0.54%	-18.74%

08/05	Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma	CI
06/02	US FDA OKs Acepodia's Investigational New Drug Application for Cancer Treatment	MT

Acepodia, Inc.(TPEX:6976) added to S&P Global BMI Index

December 18, 2023 at 10:30 am IST

Latest news about Acepodia, Inc.

Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma	08/05	CI
US FDA OKs Acepodia's Investigational New Drug Application for Cancer Treatment	06/02	MT
Acepodia Biotech, Inc. Announces Clearance of Investigational New Drug Application by U.S. Food and Drug Administration for Investigational Product ACE2016	02/02	CI
Acepodia, Inc.(TPEX:6976) added to S&P Global BMI Index	18/12	CI
Acepodia Appoints Nobel Laureate Carolyn Bertozzi as Chief Scientific Advisor	18/23/18	CI

Acepodia Inc is engaged in the research and development of new anti-cancer drugs. The Company uses antibody-cell conjugation (ACC) and immune cells. The products include Gamma delta 2T cell platform including ACE1831 (ACE-gdT-CD20) an antibody linked to specific target CD20 for treatment of lymphoma, ACE2016 (ACE-gdT-EGFR) an antibody linked to specific target EGFR , the target treatment of EGFR+ solid tumors, such as lung cancer, ACE1708 (ACE-gdT-PDL1) an antibody linked to the specific target PDL1 antibody, the target treatment of solid tumors; off-the-shelf natural killer (oNK) cell platform including ACE1702 (ACE-oNK-HER2) linked to a specific target HER2 antibody, targeting treatment of HER2+ solid tumors, such as breast cancer. The technologies include antibody cell linking technology, Gamma delta 2T cell screening, culture and amplification technology, oNK cell culture and amplification technology, Acepodia series of new cell drug preparations freezing and thawing technology.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACEPODIA, INC.	-18.74%	495M
MODERNA, INC.	+43.36%	58.06B
IQVIA HOLDINGS INC.	-5.31%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B
BIO-TECHNE CORPORATION	+0.04%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.12%	12B
MEDPACE HOLDINGS, INC.	+26.04%	11.92B